Pfizer sells midphase inflammatory drugs to mystery startup, exiting race against Bristol Myers
Pfizer is getting out of TYK2. Having studied its lead inhibitor in a raft of
Pfizer is getting out of TYK2. Having studied its lead inhibitor in a raft of